Overview Elranatamab in Patients with Relapsed or Refractory AL Amyloidosis Status: RECRUITING Trial end date: 2029-09-01 Target enrollment: Participant gender: Summary This study will evaluate the safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis.Phase: PHASE1 Details Lead Sponsor: Brigham and Women's Hospital